Session » (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1135

A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate

10:30AM-12:30PM: Abstract Number: 1133

A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition

10:30AM-12:30PM: Abstract Number: 1144

A quantitative study of renal medulla echogenicity in 250 Vietnames gout patients shows correlation with poor renal function

10:30AM-12:30PM: Abstract Number: 1124

ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations

10:30AM-12:30PM: Abstract Number: 1128

Association between leptin levels, body mass index and health-related quality of life in patients with gout

10:30AM-12:30PM: Abstract Number: 1146

Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study

10:30AM-12:30PM: Abstract Number: 1126

Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1132

DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk

10:30AM-12:30PM: Abstract Number: 1129

Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic

10:30AM-12:30PM: Abstract Number: 1134

Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1138

Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi

10:30AM-12:30PM: Abstract Number: 1143

Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database

10:30AM-12:30PM: Abstract Number: 1137

Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1141

Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages

10:30AM-12:30PM: Abstract Number: 1123

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study

10:30AM-12:30PM: Abstract Number: 1130

Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia

10:30AM-12:30PM: Abstract Number: 1145

Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout

10:30AM-12:30PM: Abstract Number: 1140

PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs

10:30AM-12:30PM: Abstract Number: 1139

Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations

10:30AM-12:30PM: Abstract Number: 1136

The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts

10:30AM-12:30PM: Abstract Number: 1127

The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices

10:30AM-12:30PM: Abstract Number: 1142

Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD

10:30AM-12:30PM: Abstract Number: 1125

Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout

10:30AM-12:30PM: Abstract Number: 1131

Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].